due dilig valuat report
market cap date
inc compani
follow separ
compani develop biolog four primari area
focu immunolog oncolog virolog
addit biolog compani small
rang tradit pharmaceut drug
inherit abbott non-biolog
contribut materi compani revenu
gener sell product directli
health care facil specialti pharmaci
market co-promot product
abbvi key treatment humira imbruvica
mavyret orilissa elagolix humira
highest sell treatment drug histori
anti-tnf monoclon antibodi current treat
rheumatoid arthriti
ulcer coliti among mani diseas
humira account revenu
revenu took
hundr patent us
patent europ protect humira
humira composition-of-matt patent expir
decemb us octob
of-matt patent expir us earlier
decemb short exist off-
composition-of-matter-pat treatment europ
humira face stiff competit biosimilar
offer deep discount prevent
sharp fall humira revenu
humira key european patent expir key
us patent expir four year abbvi
pressur make loss
humira revenu well find altern
growth catalyst acquisit allergan step
direct
mani compani treatment includ
imbruvica mavyret orilissa skyrizi
potenti blockbust togeth
make humira revenu loss also gener
growth top
arrowhead updat coverag
fair valu bracket base
discount valuat compar
due dilig valuat report
import disclosur page report
humira continu face stiff competit
biosimilar europ
nine month composition-of-matt
patent expiri thing look wors expect
humira face stiff competit
biosimilar differ countri
result declin humira non-u
revenu comparison
compani increas estim non-u
humira revenu declin
previou estim declin
believ may discount humira
 europ follow
discount
respect base exampl biolog
gone composition-of-matt patent
past believ discount
continu increas price
stabil thereaft would result overal
declin humira non-u revenu
allergan acquisit diversifi abbvi
portfolio increas cash flow
announc acquisit allergan
billion cash stock deal june
second-largest healthcar
acquisit till date
acquisit diversifi abbvi portfolio
increas size non-humira portfolio
acquisit also expect creat
billion synergi increas cash flow
use cash pay debt
strengthen pipelin support
target immunotherapi
acquisit mavupharma
strengthen early-stag oncolog
pipein acquisit mavupharma
focus sting pathway strong
pipelin early-
treatment venclexta imbruvica
acquisit
develop
mavupharma platform provid abbvi
treatment like make humira
revenu loss europ
seven biosimilar develop
licens agreement allow develop
biosimilar launch market
humira gone composition-of-matt
patent made term
alreadi promis treatment
market plan launch
promis treatment expect
humira royalti non-humira portfolio
exist entiti exclud acquisit
allergan mavupharma gener annual
revenu billion
make expect loss humira
revenu well gener addit revenu
humira expect experi mute
growth us due market satur
revis revenu estim
humira downward base abbvi latest
guidanc humira revenu grew
although humira price increas
jan growth revenu
treatment attribut price
increas limit major humira
revenu growth driven
revenu grow billion translat
growth rate believ humira
revenu growth continu slowdown
futur therapi demand approach
satur us
earli indic
regulatori headwind could advers affect
revenu growth opinion greatest
immin sourc regulatori risk
due dilig valuat report
import disclosur page report
industri fall treatment price due
twin drug price control act sign
presid increas input cost
on-going us-china trade war potenti
expedit approv process biosimilar
food drug administr fda new
make effort build humira brand
loyalti creat switchov cost
exclus claus rebat
believ would prevent europe-lik quick
steep drop humira us revenu humira
remain us patent expir
treatment plaqu psoriasi
skyrizi risankizumab got fda approv april
treatment moder sever
plaqu psoriasi adult patient
candid systemat therapi treatment
better efficaci peer
expect quickli gain market
share skyrizi current test sever
indic includ ulcer coliti
crohn diseas expect gener peak
revenu billion
success upcom treatment
critic vindic research-bas tag
biopharmaceut compani much greater
focu develop new biolog howev
treatment compani
develop
intern mavyret
pharmaceut abbvi top-sel
treatment acquisit
cancer drug
venclexta novemb much-
partnership
anticip psoriasi treatment skyrizi april
compani expect unveil
intern develop biolog next two
year biolog come lot
promis import live
promis vindic tag
partnership asia may becom import
growth driver long-term
market biopharmaceut becom
increasingli attract asia especi india
china japan major economi southeast
asia larg due polici reform
entrepreneuri cultur biopharmaceut
develop attract mani global
asia
result mushroom biopharmaceut
startup region particularli china
young chines compani conduct trial
quarter innov asset beyond
china mani case partnership
lead global biopharmaceut compani
 commerci front
asia market key strateg focu
present compani
expect asia contribut materi futur
revenu howev compani look
strateg partner help expand busi
china major asian market
capabl make strong strateg fit
young asian compani asia becom
high-growth geographi biopharmaceut
partnership could import sourc
long-term growth
strong
due dilig valuat report
import disclosur page report
tabl content
stock inform error bookmark defin
manag govern
note refer
due dilig valuat report
import disclosur page report
list new york stock exchang divestitur januari
incorpor north chicago illinoi januari spun abbott
laboratori abbott claim object spin-off separ two fundament differ
busi distinct strateg profil busi prioriti effect revers integr
upon complet medic product busi came abbott laboratori
research-bas pharmaceut busi came
list new york stock exchang nyse open price per share
januari follow privat distribut billion equiti share compani began trade
nyse ticker market capit base issu price billion
under-perform last week rel competitor major indic
abbvi stock significantli under-perform three relev major indic week
august period stock gener return
russel nasdaq biotechnolog indic gener return
respect under-perform five closest nasdaq-list competitor viz neurocrin
bioscienc gilead scienc celgen stock declin sinc
januari nasdaq biotechnolog index gone period
impli stock under-perform market
one consist high dividend pay biopharmaceut stock compani
increas dividend averag annual last three year increas
dividend annual last consecut year includ dividend paid abbott
june declar quarterli cash dividend per share per share
annual basi third consecut quarter compani maintain dividend
pay-out compani current dividend yield higher yield
due dilig valuat report
import disclosur page report
inc compani illinois-bas research-driven compani
discov develop manufactur sell pharmaceut product compani work
virolog neurosci
revenu billion oper countri market capit
billion among largest biotechnolog compani world abbvi
blockbust anti-inflammatori treatment humira highest sell medicin histori
billion sale sinc launch humira gener revenu billion
abbvi major treatment includ imbruvica mavyret hcv compani pipelin
treatment indic clinic develop individu collabor
mid- late-stag develop
busi built strong acquisit market capabl need vindic tag
research-bas biopharmaceut compani
claim research-bas biopharmaceut compani much greater focu
develop new biolog develop biosimilar compani long pipelin intern
develop biolog variou stage test mani phase iv test
expect get fda approv
compani shown strong abil identifi biolog encourag market potenti
test acquir right acquir compani creat
underli technolog compani excel ringfenc acquir technolog patent
use consider market distribut muscl maxim revenu compani
revenu sinc spin-off abbott almost entir come biolog develop
anoth compani oppos develop
acquir part basf knoll pharmaceut co unit
acquir global right million
acquir acquisit pharmacycl billion
acquir acquisit stemcentrx billion
abbvi success thu far larg hing abil spot treatment strong potenti
market treatment great commerci success strong market distribut
compani expect unveil intern develop biolog next two year
biolog come lot promis import live
promis vindic tag research-bas biopharmaceut busi
due dilig valuat report
import disclosur page report
humira account abbvi
decreas depend humira
abbvi flagship biolog humira best-
sell treatment histori anti-tnf
monoclon antibodi current treat
arthriti ankylos spondyl uveiti
humira gener revenu billion
account total
year humira revenu
contribut decreas
predominantli due declin
non-u revenu biosimilar enter
european market increas
revenu contribut imbruvica mavyret
newer treatment demand humira us approach satur sooner
expect anoth key contributor fall humira revenu contribut compani hcv
portfolio cancer treatment imbruvica account revenu despit
factor humira still remain singl largest revenu contributor acquisit
allergan along plan launch sever promis treatment decreas
depend humira
stiff competit biosimilar result declin non-u humira revenu
us decemb
european union eu octob
patent expir decemb humira
composition-of-matt patent eu
expir compani face direct
europ
contribut approxim humira
non-u revenu approxim
humira non-u revenu declin
billion billion
declin consequ
stiff competit face biosimilar
humira non-u revenu declin
humira non-u revenu bn
inc annual report arrowhead
humira key revenu dynam europ chang volum price
lower depend price advantag environ larger us
sector appear head pricing-rel regulatori headwind howev
believ competit depend heavili price biosimilar price much lower
due dilig valuat report
import disclosur page report
cost humira significantli reduc price compet cheaper
acquir humira part billion acquisit basf us busi
compani protect humira ever sinc wall patent typic pharmaceut drug
dont patent biolog humira protect patent
sinc made live cell creat involv step greater complex abbvi
secur us patent humira make difficult compani
replic treatment without use process techniqu pharma giant continu
humira royalti could provid support humira non-u revenu declin
increas expect non-u humira revenu drop
octob compani increas estim humira
non-u revenu declin repeat downward revis indic
threat humira face biosimilar
believ compani latest revenu declin expect humira also conserv
forc reduc humira price europ result greater revenu
declin compani expect believ compani continu reduc price
europ result sharp revenu declin next three year
sign non-exclus patent licens agreement seven humira biosimilar develop
latest addit list royalty-bas agreement allow humira biosimilar
develop sell mani countri around world keep biosimilar bay us till
see tabl expect royalti agreement increas consist
partli make declin humira non-u revenu
entri date us
humira us revenu expect experi mute growth due market satur
regulatori headwind
humira us revenu larg driven volum growth although humira price increas
jan growth revenu treatment attribut price increas
limit expect humira us revenu grow billion translat growth rate
contribut price increas expect low singl digit percentag
due dilig valuat report
import disclosur page report
growth prescript volum increas expect contribut rest believ humira
revenu growth continu slowdown futur therapi demand approach
satur us
humira us revenu growth slow
humira us revenu bn
inc annual report arrowhead
total revenu declin
humira total revenu bn
inc annual report arrowhead
compani also make effort build humira brand loyalti creat switchov cost
exclus claus rebat prevent europe-lik quick steep drop humira us
revenu remain patent expir earli indic
biopharmaceut busi could face stiff regulatori headwind could moder revenu growth
opinion three greatest immin sourc regulatori risk industri fall treatment
price due twin drug price control act sign presid increas input cost
on-going us-china trade war potenti expedit approv process biosimilar food
drug administr fda new biosimilar action
allergan acquisit diversifi portfolio enhanc cash flow
announc acquisit allergan billion cash stock deal june
second largest healthcar deal year allergan sharehold receiv share abbvi
cash allergan share translat total consider per share
consider impli premium allergan close price june
allergan ireland-bas healthcar compani focus develop commerci
pharmaceut biolog medic devic compani best known non-surg cosmet
motiv behind acquisit diversifi portfolio increas size non-
humira portfolio allergan acquisit expect creat synergi billion provid
enhanc cash flow cash flow use pay debt rais acquisit invest
strengthen pipelin support grow dividend pay-out
due dilig valuat report
import disclosur page report
impact acquisit
allergan acquisit unexpect sinc announc end
look make major acquisit short-term would instead focu strengthen
allergan loss-mak compani acquisit seem portfolio top line
synergi howev anticip numer synergi acquisit includ annual pre-
tax save cost reduct least billion third year deal complet billion
cost reduct expect come
portfolio two compani overlap treatment brain women health stomach
disord acquisit expect deliv new sourc growth compani struggl
find
botox allergan flagship beauti treatment expect continu strong growth
botox power poison made neurotoxin call botulinum toxin number applic
use correctli use medic certain muscular condit cosmet remov
wrinkl temporarili paralyz muscl
botox gener revenu billion translat allergan revenu
billion botox revenu came cosmet use govern includ botox
list prescript medic henc buffer treatment price pressur health
insur govern health agenc put prescript medicin
botox secur approv nine indic fda includ bladder dysfunct chronic
migrain expect keep grow therapeut well cosmet treatment botox
expect gener revenu billion nearli billion accord refinitiv
target immunotherapi acquisit mavupharma
enhanc early-stag oncolog pipelin acquisit mavupharma seattl base
biopharmaceut compani focus sting pathway mavupharma focus discoveri
develop novel approach target sting stimul interferon gene pathway
signal link pathway known play import role gener immun respons
tumor mavupharma uniqu approach focus block key neg regul sting
pathway oppos directli stimul sting avoid overstimul pathway
high level cytokin releas
strong pipelin earli late stage oncolog treatment venclexta imbruvica
mavupharma platform provid potenti develop immuno-oncolog portfolio
due dilig valuat report
import disclosur page report
pipelin look strong sever promis treatment
 spend bn
although continu heavili humira-
depend expect depend humira
come consider next five year
sinc spin-off abbott
build strong medicin pipelin
diversifi revenu away humira
invest billion
research
develop
expenditur billion
increas compani
invest billion market research firm
evaluatepharma iii rank pipelin
second term valu creation pipelin
product forecast cumul sale
billion believ
compani continu increas invest add pipelin
consist high spend help
inc annual report arrowhead
non-humira treatment expect boost revenu go forward
current medicin
variou stage test compani
launch three new treatment
plan launch two treatment
treatment launch
wit appreci initi uptak
expect two treatment also
also sever promis medicin
pipelin phase
test better compani expect
launch expect
new medicin along exist
non-humira treatment account
compani revenu
strong exist upcom therapi
non-humira revenu bn
inc annual report arrowhead
abbvi key non-humira treatment spread across oncolog immunolog gener medicin
strong oncolog portfolio includ imbruvica venclexta two therapi
togeth gener billion revenu oncolog portfolio major growth
contributor compani expect signific growth therapi revenu
imbruvica project reach billion estim could reach billion
imbruvica imbruvica ibrutinib first-in-class bruton tyrosin kinas btk inhibitor avail
 sinc fda-approv use treatment total nine indic includ
five b-cell blood cancer chronic graft-versus-host-diseas imbruvica jointli develop
due dilig valuat report
import disclosur page report
commerci johnson johnson-own janssen revenu split equal
janssen biotech treatment gener billion revenu
translat total revenu
venclexta venclexta select small molecul inhibitor investig treatment
multipl cancer approv chronic lymphocyt leukemia cll delet
cll-relaps refractori phase trial acut myeloid leukemia aml cll-first
line multipl myeloma mm expect venclexta gener revenu million
expect strengthen immunolog portfolio addit two next-gener therapi
name risankizumab upadacitinib file biolog licens applic bla fda
risankizumab upadacitinib expect obtain approv second half
skyrizi skyrizi risankizumab got fda approv april treatment moder
sever plaqu psoriasi adult patient candid systemat therapi treatment
better efficaci dose schedul comparison peer expect
quickli gain market share skyrizi current test sever indic includ
ulcer coliti crohn diseas expect gener peak revenu billion
upadacitinib upadacitinib select inhibitor investig
treatment rheumatoid arthriti crohn diseas ulcer coliti atop dermat psoriat
arthriti axial spa aim develop upadacitinib differenti treatment
rheumatoid arthriti treatment current prioriti review expect gener peak
revenu billion
orilissa elagolix orilissa first fda-approv oral treatment manag moder
sever pain associ endometriosi decad co-develop treatment
treatment receiv fda approv prioriti review juli
roll us august orilissa also approv health canada octob
august announc posit result phase-iii studi use orilissa
treatment uterin fibroid compani expect file bla
expect orilissa anoth blockbust given huge market endometriosi
treatment us endometriosi affect estim one ten american women reproduct
orilissa expect directli compet allergan uterin fibroid treatment esmya
await fda approv fda declin approv esmya august way clear
orilissa quickli corner larg share market fear around safeti orilissa
fda declin approv esmya august due esmya harm side effect
patient liver fear quell fda approv orilissa requir carri
black box warn given support market condit orilissa expect treatment
well feel favor posit achiev revenu project
billion compani expect orilissa gener revenu million
due dilig valuat report
import disclosur page report
mavyret mavyret once-daili co-formul hcv treatment includ glecaprevir broad-
genotyp proteas inhibitor pibrentasvir inhibitor approv
fda august surpris success gener revenu billion
mavyret current hold global market share market posit constantli
improv due price advantag shorter respons time compar gilead harvoni
epclusa mavyret respons time week compar harvoni epclusa respons time
week
mavyret enjoy signific revenu growth billion billion
expect hcv portfolio gener revenu billion rapid growth
expect cool futur market hepat continu shrink
disappoint result rova-t late-stag trial result billion write-off
announc billion write-off invest stemcentrx disappoint result
late-stag trial lung cancer treatment rova-t compani acquir rova-t three
early-stag compound billion acquisit cancer drug develop stemcentrx
huge expect rova-t phase trial time decemb
compani halt late-stag trial rova-t lung cancer patient take drug die faster
treat standard chemotherapi rova-t failur big setback compani creat
uncertainti regard potenti treatment obtain acquir stemcentrx
sinc treatment also base concept
partnership strateg invest could add strong treatment pipelin
develop treatment partnership early-stag biopharmaceut compani focu specif
area treatment core compon product develop strategi compani
dedic ventur capit arm make strateg invest young compani
strong treatment discoveri pre-clin stage
compani enter sever partnerships-with-invest agreement recent year
includ bioarctic collabor swedish biotechnolog
firm bioarctic septemb co-develop three treatment parkinson diseas two
compani also co-develop imag biochem marker parkinson diseas
enter partnership voyag therapeut februari co-develop potenti new
treatment alzheim diseas tau-rel neurodegen diseas collabor
includ develop gene therapi treatment tau abbvi key recent
partnership early-stag compani mention follow tabl
due dilig valuat report
import disclosur page report
neurodegener cancer
dna mutat tumor
cancer seriou diseas
solut carrier famili transport
drug-resist microbi infect cancer
immunolog fibrot neoplast vascular diseas
cancer seriou diseas
tissu repair regener
first-in-class immunotherapi cancer
novemb announc set new squar feet hub south
san francisco intend hous staff believ one princip
motiv set site close proxim partner compani cytomx
expect compani strengthen capabl mani
new collabor partner
due dilig valuat report
import disclosur page report
acquir mavupharma enhanc early-stag oncolog pipelin
announc acquisit mavupharma seattle-bas biopharmaceut compani focus
novel approach target sting stimul interferon gene pathway treatment
announc acquisit allergan billion cash stock deal
allergan announc compani enter definit transact agreement
acquir allergan cash stock transact transact equiti valu
approxim billion base close price common stock june
fda lift partial clinic hold phase studi venetoclax patient multipl myeloma
fda lift partial clinic hold place canova phase trial evalu venetoclax venclexta
investig treatment relapsed/refractori multipl myeloma canova trial evalu
venetoclax combin dexamethason versu pomalidomid combin dexamethason
patient relapsed/refractori multipl myeloma posit transloc abnorm
venclexta approv fda chemotherapy-fre combin regimen previous untreat
fda approv venclexta combin obinutuzumab gazyva previous untreat patient
chronic lymphocyt leukemia small lymphocyt lymphoma fda grant breakthrough
therapi design combin therapi
humira patent litig boehring ingelheim resolv
us humira patent litig boehring ingelheim resolv term
resolut grant boehring non-exclus licens humira-rel intellectu properti
unit state licens boehring begin juli boehring pay
royalti licens humira patent make payment form
skyrizi risankizumab get approv european commiss treatment plaqu psoriasi
european commiss ec approv skyrizi risankizumab treatment moder sever
plaqu psoriasi adult patient candid system therapi approv allow
market skyrizi member state european union well iceland liechtenstein
due dilig valuat report
import disclosur page report
strateg transact teneobio develop new treatment multipl myeloma
enter strateg transact teneobio inc affili teneoon inc
develop commerci bcma target immunotherapeut potenti treatment
multipl myeloma
fda approv use imbruvica along obinutuzumab
announc fda approv use imbruvica combin obinutuzumab adult
patient previous untreat chronic lymphocyt leukemia small lymphocyt lymphoma
first chemotherapi free combin regimen approv chronic lymphocyt leukemia/smal
lymphocyt lymphoma previous untreat patient
strateg collabor tizona develop first-in-class immunotherapi cancer
enter strateg collabor privat held immunotherapi compani tizona
therapeut inc develop commerci therapeut includ first-
in-class antibodi treatment cancer
due dilig valuat report
import disclosur page report
abbvi inc headquart north chicago illinoi list nyse nyse
sharehold structur march
ownership
ownership compani higher
compani
broader
interest larg
consist paid high dividend
index fund
vanguard group inc blackrock inc
jointli hold stake
ownership lie
high institut interest also attribut compani strong rel stabl current
busi long pipelin potenti blockbust treatment increas compani growth
expect time potenti add revenu stabil
top sharehold februari
ordinari share
capit research manag compani
due dilig valuat report
import disclosur page report
nyse
due dilig valuat report
import disclosur page report
manag govern
chairman board chief execut offic
mr gonzalez director board sinc
mr gonzalez join abbott held variou manag posit briefli retir
includ abbott presid chief oper offic presid chief oper offic
abbott medic product group senior vice presid presid abbott former hospit
product divis vice presid presid abbott health system divis division
presid gener manag abbott diagnost oper unit state canada
also serv presid abbott ventur inc abbott medic technolog invest arm
ms alban vice chairman chief commerci offic sinc
respons global commerci oper compani includ pharmacycl
commerci function previous serv execut vice presid commerci oper
mr alban join abbott held variou manag posit includ senior vice
intern pharmaceut vice presid western europ canada vice presid
vice chairman extern affair chief legal offic
ms schumach vice chairman extern affair chief legal offic sinc
respons legal ethic complianc corpor govern corpor aviat
corpor respons brand commun previous serv execut vice
presid extern affair gener counsel corpor secretari
previous led abbvi licens acquisit ventur earli stage collabor
ms schumach join abbott respons abbott offic ethic
complianc spun abbott ms schumach serv execut vice
presid gener counsel corpor secretari
also serv board gener dynam corpor
due dilig valuat report
import disclosur page report
vice chairman presid
dr severino vice chairman presid sinc
respons research develop human resourc oper corpor
join execut vice presid research develop chief scientif
prior join dr severino serv amgen inc held variou manag posit
includ senior vice presid global develop corpor chief medic offic vice
presid global develop vice presid therapeut area head gener medicin
mr chase execut vice presid financ administr sinc
respons financi administr function compani previous serv
execut vice presid chief offic
mr chase join abbott held variou manag posit includ vice presid
licens acquisit vice presid treasur division vice presid control abbott
execut vice presid chief strategi offic
mr gosebruch join execut vice presid chief strategi offic
prior join mr gosebruch work merger acquisit group jp morgan
secur llc year serv manag director sinc co-head
north america
mr richmond execut vice presid chief offic sinc
previous serv senior vice presid human resourc
mr richmond join abbott held variou manag posit includ division vice
presid compens benefit group vice presid reward division vice
presid talent acquisit
due dilig valuat report
import disclosur page report
dr saleki-gerhardt execut vice presid oper sinc
previous serv senior vice presid oper
dr saleki-gerhardt join abbott held variou manag posit includ vice
presid pharmaceut manufactur suppli division vice presid qualiti assur
also serv board entegri inc
dr donogho join senior vice presid enterpris innov
previous serv mckinsey compani lead firm west coast pharma
biotechnolog practic dr donogho join firm support multipl success
launch therapeut area oncolog immunolog primari care
mr michael senior vice presid chief offic sinc
mr michael join hekd variou manag posit includ vice presid
control treasur vice presid control commerci oper vice presid
plan analysi
mr michael join abbott serv divis control nutrit suppli chain
mr stewart senior vice presid commerci oper sinc
previous serv presid commerci oper
mr stewart join abbott serv vice presid abbott proprietari pharmaceut
divis unit state prior separ abbott
due dilig valuat report
import disclosur page report
mr durkin vice presid control sinc
mr durkin previous serv vice presid intern audit
mr durkin join abbott held variou manag posit includ vice presid
financ divis control abbott vision busi control pharmaceut
research develop
due dilig valuat report
import disclosur page report
industri expect maintain growth momentum strong growth biosimilar
global industri gener revenu billion repres
growth industri revenu billion north america highest
revenu gener industri share global revenu europ second-
highest revenu gener share
industri expect continu grow compound-annual-growth-rate reach revenu
billion growth expect broad-bas europ north america
maintain high-growth momentum emerg market led china asian emerg
market join
origin treatment biosimilar biosimilar expect experi higher revenu
growth revenu biosimilar expect grow compound-annual-growth-rate europ
north america expect experi equal impress growth emerg market
especi china estim compound-annual-growth-rate
global biopharma market expect
reach billion
north america largest biopharma
market revenu share
rest world
strong industri growth led signific increas equiti transact
us
sector experienc strong financ ipo activ transact
valu volum first nine month higher full year expect
continu grow come quarter
financ transact sector wit financ transact first
nine month total transact valu billion compar transact worth
billion whole term number deal first three quarter
almost par full year deal complet
ipo term ipo saw ipo first nine month total
valu billion compar ipo total deal valu billion
due dilig valuat report
import disclosur page report
follow equiti offer also strong expect continu strong long
volatil us equiti market hamper alloc
 transact first three quarter saw complet
transact total valu billion number transact exactli par full
year deal valu doubl billion vibranc market larg
due compani look inorgan build portfolio addit indic strengthen
think increas competit space larg compani broader
pharmaceut space look increas busi market
continu strong
us-china trade war could hurt industri china
us-china trade war potenti caus signific damag industri
countri china appear upper hand
april us trade repres ustr announc intent impos tariff
product categori import china import estim worth billion
mani use drug manufactur process
respons china impos duti us good us govern respond ask
ustr consid addit tariff estim worth chines import us
govern place tariff raw drug ingredi insulin epinephrin vaccin
feel impos tariff go us govern attempt reduc drug price includ
sign lowest price act patient right drug price act tariff could
also cap price biopharmaceut discourag invest could hurt innov
longer run
accord globaldataiv china current appear much better posit negoti
standpoint chines biopharmaceut industri seem threaten move
uncertainti new propos tariff may diffus entir valu chain biopharma
industri neg affect us patient payer gener biosimilar drug maker
asia look set becom new biopharmaceut industri growth engin
market action biolog larg concentr western europ north america
howev emerg market especi asia pacif expect play equal role
emerg asian market china india japan southeast asia strateg import
biolog year absenc rudiment direct conveni biosimilar approv
pathway prevent biolog flourish market addit inconduc econom
environ creat market restrict china auster measur japan econom slowdown
india southeast asia etc imped growth biosimilar market thing seem
chang speedili better enabl polici reform vibrant entrepreneuri cultur
biopharmaceut increas early-stag invest biopharmaceut
due dilig valuat report
import disclosur page report
china like fastest grow major emerg market
china world second-largest biotech market us prospect biolog appear
encourag china countri undertak seri action promot biopharmaceut
gener pharmaceut govern infus billion dollar biopharmaceut
initi made china effort bring foreign-educ profession back
work well close life scienc profession return china
local biopharmaceut compani race ahead china accord mckinsey
whitepaperv combin support policymak influx high-qual talent capit
inject seen china innov system start come togeth mani qualiti local biotech
first half venture-capit invest billion china biotech compani twice
billion invest period part invest came vc saw
opportun exit profit short period time approxim biotechnolog ipo
complet month novemb combin valu billion compar
us peer china biotechnolog compani show significantli higher market valu
major reason accomplish local biopharmaceut compani close
innov molecul pipelin phase chines compani
conduct trial quarter innov asset beyond china either alon
partnership biotech compani activ partner lead global biopharmaceut compani
 commerci front asset-level partnership remain activ
cfda reform pay accord mckinsey whitepap past two three year
china food drug administr cfda reform help address critic gap system
exampl effort clear registration-appl backlog result signific acceler
review timelin addit publish seri reform design improv
registr process encourag compani bring innov china
cfda reform led record new product launch china versu five six
year end candid grant prioriti review
statu gear launch come year
cfda enter next phase reform pave way integr global
market mckinsey expect reform pave way signific number new molecul
reach market next year multi-national corpor local compani creat
competit environ develop commerci
biosimilar threat real immin origin biolog develop
space overwhelmingli domin origin biolog present mani
blockbust origin biolog patent protect present howev domin could come
significantli origin biolog combin revenu billion go patent
patent expiri biolog enabl biosimilar enter market
mckinseyvi expect revenu biosimilar tripl reach billion soon thereaft
revenu biosimilar expect grow reach close billion market
biosimilar expect continu grow us europ regulatori environ
becom increasingli amic biosimilar gain wider accept equal origin biolog term
safeti efficaci immunogen
due dilig valuat report
import disclosur page report
biosimilar us accord rand corporationvii biosimilar save health system
close billion next decad howev recent us protect origin
drug innov resultantli lag europ stimul growth biosimilar sinc
sever regulatori initi taken support biosimilar major recent develop
releas fda biosimilar action fda releas biosimilar action octob
two import area plan focuss improv effici
biosimilar develop approv process support market competit reduc
game fda requir attempt unfairli delay market competit
biosimilar plan expect fast-track approv process biosimilar increas
competit biolog
biotechnolog recognit critic technolog treasuri depart
includ research develop biotechnolog among critic technolog industri
subject new pilot program expand scope transact subject review
committe foreign invest unit state cfiu chair treasuri
pilot program author foreign invest risk review modern act
firrma enact august design assess nation secur impact non-
control invest made peopl oversea busi interim rule
implement pilot program took effect novemb
biosimilar europ europ ahead us advanc biosimilar
enabl regulatori environ biosimilar europ especi respect patent
regul critic reason
european market estim worth close billion boost launch
biosimilar least five biolog includ humira nordic uk among strongest
geographi biosimilar europ part europ franc expect wit
biosimilar gain wider accept europ equal origin biolog term safeti
efficaci immunogen accord mckinsey publish literatur biosimilar also
mount recent mckinsey report refer literatur review compil studi
look switch biosimilar found great major public report
differ immunogen safeti efficaci switch
due dilig valuat report
import disclosur page report
overli reliant humira expiri humira
composition-of-matt patent europ worse-
than-expect impact impact expiri
humira remain us patent uncertain
although ampl resourc financ
oper yet intern develop commerci
treatment either one-of-a-kind product
signific competitor patent protect long
overdepend key individu
board director experienc independ
risk definit patent provid market exclus biolog prohibit drug develop
creat biolog use process origin develop patent protect provid
biolog develop greater strateg advantag tradit pharmaceut compani sinc
patent differ part treatment develop process keep treatment
patent protect extend period time fifteen year case
biopharmaceut compani high patent expiri risk major treatment face
immin patent expiri especi patent expir composition-of-matt patent
mani less expens biosimilar pois eat revenu case patent expiri
hurt revenu biosimilar cost significantli less origin treatment
origin treatment manufactur limit abil close price gap
risk analysi origin treatment young patent-protect mani
year key market us europ therefor believ treatment low
patent expiri risk howev biolog account revenu
revenu come humira went composition-of-matt patent
europ octob go remain us patent offer
heavi discount humira short aftermath patent expiri expect drastic fall humira
due dilig valuat report
import disclosur page report
